Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT03593837 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Efficacy and Safety of HQGZWWT Patients With Rheumatoid Arthritis

Start date: October 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling, pain, and synovial damage. Effective methods lack in the treatment of RA. A traditional prescription in use for thousands of years in China, Huang Qi Gui Zhi Wu Wu Tang(HQGZWWT)granule is still chosen to relive pain and prevent joint malformation in RA patients. However, no evidence-based medical research has been organized to assess the effectiveness and safety of HQGZWWT granules for RA.

NCT ID: NCT03508713 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)

LELAND
Start date: May 13, 2018
Phase:
Study type: Observational

To focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA. To explore the factors which influence the treat-to-target outcome.

NCT ID: NCT03506035 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis

ABSEC
Start date: September 1, 2018
Phase:
Study type: Observational

Rheumatoid arthritis (RA) is an autoimmune and sistemic disease,characterized by joint sinovitis and the production of autoantibodies (Ab). The Ab against citrullinated peptides (ACPA) are the most specific (92-98%), and high sensitivity (75-81%) and they are of prognostic value. ACPA are already in the beginning of the disease in most cases, having been found years before its onset. Recent studies have suggested that ACPA may have a role in perpetuating inflammation, in the generation of bone erosions and in pain in RA. Citrullination is a post-translational modification mediated by the PAD, which transforms an arginine into a citrulline. In vivo, this enzyme acts in proinflammatory environments. Despite being widely studied, none of the natural citrullinated substrates have been shown to be the triggering and/or perpetuating factor in the response of B cells in RA, understanding this response as the production of ACPA. In fact, the most specific and sensitive commercial test for the detection of ACPA uses synthetic peptides protected by a patent. In the other hand, the genetic factor that most increases susceptibility to develop RA is a shared sequence of aminoacids (QKRAA, QRRAA i RRRAA), in the HLA-DRB1 gene, known as the shared epitope (SE). Also, SE, confers prognostic value, and is associated with the presence of ACPA. These SE sequences contain arginines (R), which are susceptible to be citrullinated by the PAD enzyme. We propose the hypothesis that citrullinated SE act as an antigen capable of activating the inflammatory response mediated by B and T cells in RA. The recognition of an HLA as a foreign one, would originate an answer of alloimmune type, not valued to date. The objective of the study is to test the immune response mediated by B cells and T cells, in cases and control samples, through an in vitro model that confronts them with peptides containing the citrullinated-SE sequence. In addition, we will evaluate the association between these results with the clinical features of cases (RA included in the study). Their role as a biomarker, as well as their potential to improve the tests currently available to detect ACPA will be explored.

NCT ID: NCT03390920 Not yet recruiting - Osteoarthritis Clinical Trials

Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for pain relief and functional improvements for all types of musculoskeletal conditions. The study is prospective, with outcome measures being obtained at numerous time points after the regenerative procedure.

NCT ID: NCT03365856 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Remission in Rheumatoid Arthritis in the Asian-Pacific Region

Start date: January 1, 2018
Phase: N/A
Study type: Observational

This study is the multi-center, open and cross-sectional study of RA remission in Asia Pacific region. The objectives is to explore remission rate of RA patients in different countries in the Asian-Pacific area using different criteria of remission (DAS28, CDAI, SDAI, ACR/EULA remission criteria, RAPID3 and Clin28) and investigate the associated factors of remission in RA patients.

NCT ID: NCT03346590 Not yet recruiting - Clinical trials for Active Rheumatoid Arthritis

Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

Chronic inflammation in rheumatoid arthritis is associated with adiposity, sarcopenia, cachexia, reduced activity due to functional impairment, and anti-inflammatory drugs. Patients frequently gain weight when taking anti-tumor necrosis factor (TNF) medication, prompting questions about the underlying mechanism and long-term cardiovascular and metabolic tolerance associated with these drugs The primary objective of this study is to analyze the impact of anti-TNF treatment during the first year of administration on the energy metabolism of patients suffering from RA, assessed as an absolute value (before-after) and in comparison with a standard measured in healthy matched subjects.

NCT ID: NCT03324412 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis

Start date: October 28, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability. It has been confirmed that Tripterygium Wilfordii has effects of anti-inflammatory, immunosuppressive and cartilage protection. This is a multicenter ,double Blind, randomized study to evaluated the efficacy and safety of Tripterygium Wilfordii in treating of patients with rheumatoid arthritis (RA) and establish a prediction model for Tripterygium Wilfordii response of rheumatoid arthritis (RA).

NCT ID: NCT03316027 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Adherence Rate to DMARDS in Egyptian Patients With RA

Start date: November 2019
Phase:
Study type: Observational

The study aims at determining adherence rate to DMARDS and predicting factors affecting treatment adherence among sample of Egyptian patients with RA.

NCT ID: NCT03274570 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life

Start date: October 1, 2017
Phase: N/A
Study type: Observational

The aims of the research are: - To predict factors affecting hand dysfunction in patient with rheumatoid arthritis - To study the effect of hand dysfunction on quality of life in patient with rheumatoid arthritis

NCT ID: NCT03265236 Not yet recruiting - Clinical trials for Anti-MCV in Rheamatoid Arthritis

Diagnostic Value of Anti-MCV in Pts With RA

Start date: September 15, 2017
Phase: N/A
Study type: Observational

The aim of this work is to evaluate the diagnostic value of anti-MCV antibodies in rheamatoid arthritis patients and to correlate its relationtion disease activity and manifestations.